Ritonavir

Drug Profile

Ritonavir

Alternative Names: A 84538; ABT 538; Norvir

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Gilead Sciences; RP Scherer
  • Class Amides; Antiretrovirals; Carbamates; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV infections
  • Registered HIV-1 infections

Most Recent Events

  • 07 Jun 2017 Registered for HIV-1 infections (In infants, In children, In adolescents) in USA (PO)
  • 11 Jan 2017 Ritonavir receives Orphan Drug status for HIV-1 infections (In adolescents, In children, In infants) in USA
  • 07 Dec 2016 Preregistration for HIV-1 infections (In infants, In children, In adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top